BofA Lowers Watson Pharmaceuticals to Neutral

Analyst David Maris cites a negative pricing environment and competition to it's Oxytrol drug

Banc of America downgraded Watson Pharmaceuticals (WPI ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.